A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.
Critical differences between dietary supplement and prescription omega-3 fatty acids: a narrative review.
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
Eicosapentaenoic acid inhibits membrane cholesterol domains compared to other omega-3 fatty acids under conditions of hyperglycemia [abstract 005].
Eicosapentaenoic acid, but not a mixed omega-3 fatty acid supplement, improved nitric oxide bioavailability in human endothelial cells in vitro.
Managing the lipid triad: improving physicians' understanding of the role of omega-3 fatty acids with CME